Zhejiang Taimei Medical Technology (HKG:2576) forecasts its net loss to narrow by 38% to 220 million yuan in 2024 from 356.4 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
The lower loss forecast is attributable to a higher overall gross profit margin and a decline in selling and research and development costs, the filing said.
The medical technology company plans to publish its annual results by the end of March.